Centrient Accuses India’s Dalas Of Amoxicillin Patent Infringement

 
• By Penelope MacRae

Centrient Pharmaceuticals, which makes “sustainable antibiotics,” has filed an Indian lawsuit in the Delhi High Court against Dalas Biotech accusing the Indian company of patent infringement over its amoxicillin trihydrate API.

Amoxicillin
Centrient’s Lawsuit Revolves Around An Amoxicillin Process Patent • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin